Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
QURE — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

22.93

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

-0.2

EPS Last/This Y

0.49

EPS This/Next Y

0.64

Price

17.13

Target Price

37.08

Analyst Recom

1.57

Performance Q

-28.78

Upside

-866.5%

Beta

0.79

Ticker: QURE



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09QURE17.970.160.11318830
2026-03-10QURE18.270.170.15315842
2026-03-11QURE17.60.180.14317255
2026-03-12QURE16.950.180.24316451
2026-03-13QURE16.940.180.27316451
2026-03-17QURE15.640.180.72319521
2026-03-18QURE14.740.180.06320664
2026-03-19QURE15.270.180.18321486
2026-03-20QURE16.120.180.12322438
2026-03-23QURE15.890.130.89262943
2026-03-24QURE15.170.120.07263244
2026-03-25QURE16.40.120.16265110
2026-03-26QURE15.610.130.87267282
2026-03-27QURE14.790.130.19268179
2026-03-30QURE14.780.131.04269132
2026-03-31QURE16.360.130.07268848
2026-04-01QURE16.90.130.73270799
2026-04-02QURE17.130.130.50272539
2026-04-06QURE17.370.130.07273118
2026-04-08QURE15.880.141.62275543
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09QURE17.97-6.3141.9-2.98
2026-03-10QURE18.26-6.338.6-2.98
2026-03-11QURE17.57-6.345.4-2.98
2026-03-12QURE16.95-6.351.5-2.98
2026-03-13QURE15.53-2.965.8-2.97
2026-03-17QURE15.62-2.964.8-2.97
2026-03-18QURE14.74-2.973.6-2.97
2026-03-19QURE15.29-2.968.1-2.97
2026-03-20QURE16.09-2.960.2-2.97
2026-03-23QURE15.90-2.962.1-2.97
2026-03-24QURE15.18-2.969.3-2.97
2026-03-25QURE16.40-2.957.0-2.97
2026-03-26QURE15.61-2.965.0-2.97
2026-03-27QURE14.81-2.972.9-2.97
2026-03-30QURE14.75-4.073.6-2.97
2026-03-31QURE16.34-4.057.7-2.97
2026-04-01QURE16.91-4.052.0-2.97
2026-04-02QURE17.15-4.049.5-2.97
2026-04-06QURE17.39-4.047.1-2.97
2026-04-07QURE17.13-4.052.0-2.97
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09QURE-6.879.9319.34
2026-03-10QURE-6.879.9319.34
2026-03-11QURE-6.879.9322.75
2026-03-12QURE-6.879.9322.75
2026-03-13QURE-6.879.9322.75
2026-03-17QURE-6.8710.2322.75
2026-03-18QURE-6.8710.2322.75
2026-03-19QURE-6.8710.2322.75
2026-03-20QURE-6.8710.2322.75
2026-03-23QURE-6.8710.2422.75
2026-03-24QURE-6.8710.2422.75
2026-03-25QURE-6.8710.2422.93
2026-03-26QURE-6.8710.2422.93
2026-03-27QURE-3.2910.2422.93
2026-03-30QURE-3.2910.2222.93
2026-03-31QURE-3.2910.2222.93
2026-04-01QURE-3.2910.2222.93
2026-04-02QURE-3.2910.2222.93
2026-04-06QURE-3.2910.2222.93
2026-04-07QURE-3.2910.2222.93
2026-04-08QURE-3.2910.2222.93
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-0.56

Avg. EPS Est. Current Quarter

-0.76

Avg. EPS Est. Next Quarter

-0.76

Insider Transactions

-3.29

Institutional Transactions

10.22

Beta

0.79

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

41

Growth Score

32

Sentiment Score

61

Actual DrawDown %

76

Max Drawdown 5-Year %

-90.1

Target Price

37.08

P/E

Forward P/E

PEG

P/S

60.8

P/B

4.98

P/Free Cash Flow

EPS

-3.48

Average EPS Est. Cur. Y​

-2.97

EPS Next Y. (Est.)

-2.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1236

Relative Volume

0.43

Return on Equity vs Sector %

-127.5

Return on Equity vs Industry %

-111

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.22

EBIT Estimation

52
◆ QURE Healthcare
$15.89
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
11/25
Volume
11/15
Valuation
10/20
TP/AR
1/10
Options
6/10
RSI
46.2
Range 1M
35.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
34 /100
WEAK
Momentum
8/25
Growth
13/30
Estimates
0/20
Inst/Vol
6/15
Options
7/10
EPS Yr
-1%
EPS NY
15.6%
52W%
12.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +133.4% upside
Quality
0/30
Valuation
14/30
Growth
8/25
Stability
5/10
LT Trend
4/5
Upside
+133.4%
Click a card to see score breakdown Full Analysis →
uniQure N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 221
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE

Latest News

—
Caricamento notizie per QURE…
stock quote shares QURE – uniQure N.V. Stock Price stock today
news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch QURE – uniQure N.V. yahoo finance google finance
stock history QURE – uniQure N.V. invest stock market
stock prices QURE premarket after hours
ticker QURE fair value insiders trading